Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Board of Directors of Henry Schein, Inc. (HSIC) and Encourages HSIC Investors to Contact the Firm
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims against certain officers and directors of Henry Schein, Inc. (NASDAQ: HSIC).
On February 12, 2018, the Federal Trade Commission disclosed that it had filed a complaint against the company for violating antitrust regulations through a conspiracy with other dental supply companies agreeing to refuse to offer discounts or service to buying groups representing dental practitioners. The company and certain of its executives were sued in an ongoing securities class action lawsuit, which charged them with failing to disclose material information and violating federal securities laws.
On August 30, 2018, the company disclosed that it expected to record a charge of $38.5 million to settle a pending antitrust class-action lawsuit filed in February 2016.
Following these disclosures, the stock price of Henry Schein fell more than 6%, closing at $67.39 per share on February 13, 2018.
If you are a long term stockholder of Henry Schein, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Henry Schein, Inc. lawsuit, please go to http://www.bespc.com/henryschein. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.